MidWestOne Financial Group Inc. Buys 4,559 Shares of Jazz Pharmaceuticals PLC $JAZZ

MidWestOne Financial Group Inc. lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 13.1% in the third quarter, Holdings Channel reports. The firm owned 39,271 shares of the specialty pharmaceutical company’s stock after buying an additional 4,559 shares during the period. Jazz Pharmaceuticals accounts for 0.6% of MidWestOne Financial Group Inc.’s investment portfolio, making the stock its 27th largest holding. MidWestOne Financial Group Inc.’s holdings in Jazz Pharmaceuticals were worth $5,176,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its position in Jazz Pharmaceuticals by 754.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 234 shares in the last quarter. Quent Capital LLC bought a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $44,000. Hantz Financial Services Inc. increased its stake in shares of Jazz Pharmaceuticals by 471.4% during the second quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after buying an additional 297 shares during the period. Geneos Wealth Management Inc. raised its holdings in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after acquiring an additional 137 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 30.7% in the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock valued at $86,000 after acquiring an additional 154 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of a number of research reports. Wells Fargo & Company raised their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, November 18th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday, October 27th. Morgan Stanley reissued an “overweight” rating and set a $225.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, January 8th. Piper Sandler reissued an “overweight” rating and issued a $219.00 price objective (up previously from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Thursday, January 29th. Fourteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $205.67.

Jazz Pharmaceuticals Trading Up 0.0%

NASDAQ:JAZZ opened at $166.31 on Friday. The stock has a market capitalization of $10.10 billion, a price-to-earnings ratio of -27.40, a PEG ratio of 0.89 and a beta of 0.26. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $182.99. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The firm has a 50 day moving average of $167.60 and a 200 day moving average of $147.00.

Insider Activity

In related news, Director Bruce C. Cozadd sold 77,500 shares of the company’s stock in a transaction dated Wednesday, November 26th. The stock was sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the transaction, the director directly owned 393,332 shares of the company’s stock, valued at $69,938,362.92. This represents a 16.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 2,238 shares of the stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $169.51, for a total value of $379,363.38. Following the completion of the sale, the senior vice president owned 19,508 shares of the company’s stock, valued at approximately $3,306,801.08. This trade represents a 10.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 123,791 shares of company stock worth $21,991,850. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.